Equities Analysts Offer Predictions for AXSM Q4 Earnings

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Zacks Research lowered their Q4 2025 earnings per share (EPS) estimates for shares of Axsome Therapeutics in a note issued to investors on Monday, November 24th. Zacks Research analyst Team now expects that the company will earn ($0.89) per share for the quarter, down from their prior estimate of ($0.64). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.37) EPS, Q4 2026 earnings at ($0.72) EPS, FY2026 earnings at ($2.19) EPS, Q1 2027 earnings at $0.69 EPS, Q2 2027 earnings at $0.58 EPS, Q3 2027 earnings at $0.51 EPS and FY2027 earnings at $1.25 EPS.

AXSM has been the topic of a number of other reports. Royal Bank Of Canada raised their target price on shares of Axsome Therapeutics from $189.00 to $198.00 and gave the company an “outperform” rating in a research note on Tuesday, November 4th. Needham & Company LLC restated a “buy” rating and set a $154.00 price target on shares of Axsome Therapeutics in a report on Tuesday, November 4th. Mizuho raised their price target on Axsome Therapeutics from $200.00 to $202.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Guggenheim lifted their price objective on Axsome Therapeutics from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Axsome Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $179.88.

Axsome Therapeutics Trading Up 0.4%

NASDAQ:AXSM opened at $150.98 on Wednesday. The company’s 50 day moving average is $130.64 and its 200-day moving average is $116.86. The company has a quick ratio of 1.51, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics has a 12 month low of $75.56 and a 12 month high of $152.94. The firm has a market cap of $7.61 billion, a price-to-earnings ratio of -29.78 and a beta of 0.50.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The business’s quarterly revenue was up 63.2% on a year-over-year basis.

Insider Activity at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 45,783 shares of Axsome Therapeutics stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $114.48, for a total transaction of $5,241,237.84. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Herriot Tabuteau sold 91,705 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70. Following the sale, the chief executive officer owned 7,229 shares in the company, valued at approximately $956,685.86. This represents a 92.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 350,577 shares of company stock worth $43,803,199 over the last three months. Company insiders own 22.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AXSM. Caitong International Asset Management Co. Ltd bought a new stake in Axsome Therapeutics in the 1st quarter valued at $25,000. Versant Capital Management Inc lifted its holdings in shares of Axsome Therapeutics by 20,300.0% during the 3rd quarter. Versant Capital Management Inc now owns 204 shares of the company’s stock worth $25,000 after acquiring an additional 203 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Axsome Therapeutics during the 1st quarter valued at about $31,000. First Horizon Corp bought a new stake in Axsome Therapeutics in the third quarter valued at about $34,000. Finally, Optiver Holding B.V. increased its stake in Axsome Therapeutics by 82.3% in the third quarter. Optiver Holding B.V. now owns 288 shares of the company’s stock valued at $35,000 after acquiring an additional 130 shares during the period. 81.49% of the stock is owned by institutional investors.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.